Assessing the determinants of the potential for cost-effectiveness over time: The empirical case of COPD

Value in Health

Volumn 16, Issue 2, 2013, Pages 426-433

  Refoios Camejo, Rodrigo ^a   McGrath, Clare ^b   Herings, Ron ^a,c   Starkie, Helen ^d   Rutten, Frans ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b ASTRAZENECA   (United Kingdom)

^c PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^d Boehringer Ingelheim   (United Kingdom)

Author keywords

chronic obstructive pulmonary disease; cost effectiveness; dynamic efficiency; pharmaceutical innovation; pharmaceutical policy; research and development

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; TIOTROPIUM BROMIDE;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICATION THERAPY MANAGEMENT; POPULATION RESEARCH; PRIORITY JOURNAL; UNITED KINGDOM;

ADRENAL CORTEX HORMONES; AGED; BODY HEIGHT; BRONCHODILATOR AGENTS; COHORT STUDIES; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; GREAT BRITAIN; HEALTH POLICY; HUMANS; MALE; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY-ADJUSTED LIFE YEARS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84875413884     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2012.11.006     Document Type: Article

References (18)

1. Refoios Camejo R, McGrath C, Rutten F. An empirical model of drug pricing and competition: a retrospective outlook of the pricing of lipid-lowering drugs. IJEBR. In Press.
2. M. Hoyle Future drug prices and cost-effectiveness analyses Pharmacoeconomics 26 2008 589 602
3. N. Gregson, K. Sparrowhawk, J. Mauskopf, and J. Paul A guide to drug discovery: pricing medicines: theory and practice, challenges and opportunities Nat Rev Drug Discovery 4 2005 121 130
4. S. Harrington Cost of capital for pharmaceutical, biotechnology, and medical device firms P. Danzon, S. Nicholson, The Oxford Handbook of the Economics of the Biopharmaceutical Industry 2012 Oxford University Press New York
5. F. Malerba, and L. Orsenigo Innovation and market structure in the dynamics of the pharmaceutical industry and biotechnology: towards a history-friendly model Ind Corpe Change 11 2002 667 703
6. R. Refoios Camejo, C. McGrath, and R. Herings A dynamic perspective on pharmaceutical competition, drug development and cost effectiveness Health Policy 100 2011 18 24
7. A. Jena, and T. Philipson Cost-effectiveness analysis and innovation J Health Econ 27 2008 1224 1236
8. R. Refoios Camejo, C. McGrath, and R. Herings Antihypertensive drugs: a perspective on pharmaceutical price erosion and its impact on cost-effectiveness Value Health 15 2012 381 388
9. European Respiratory Society and European Lung Foundation Chronic obstructive pulmonary disease European Lung White Book: The First Comprehensive Survey on Respiratory Health in Europe 2003 European Respiratory Society Journals Limited Huddersfield
10. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. 2010. Available from: http://www.goldcopd.com. [Accessed June 7, 2011].
11. World Health Organization. International Statistical Classification of Diseases and Related Health Problems 10th Revision 2007. Available from: http://apps.who.int/classifications/apps/icd/icd10online/. [Accessed September 5, 2011].
12. The Health and Social Care Information Centre. PCA prescription cost analysis data 1980-2010. 2011. Available from: http://www.ic.nhs.uk/statistics- and-data-collections/primary-care/prescriptions. [Accessed July 19, 2011].
13. Joint Formulary Committee. British National Formulary 61. London: British Medical Association and Royal Pharmaceutical Society, 2011.
14. H. Starkie Health Economic Aspects in the Management of Chronic Obstructive Pulmonary Disease 2010 Faculty of Medicine, Department of Public Health and Health Policy, University of Glasgow Glasgow
15. Office for National Statistics All Items Retail Price Index (RPI) Percentage Change Over 12 Months: Table RP04 London: Office for National Statistics 2010
16. National Institute for Health and Clinical Excellence Guide to the Methods of Technology Appraisal 2008 National Institute for Health and Clinical Excellence London
17. National Institute for Health and Clinical Excellence. Appraising Life-Extending, End of Life Treatments - Supplementary Advice to the Appraisal Committees 2009 National Institute for Health and Clinical Excellence London
18. M. le Polain, M. Franken, M. Koopmanschap, and I. Cleemput Drug reimbursement systems: international comparison and policy recommendations KCE Reports 2010 Belgian Health Care Knowledge Centre Brussels